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Abstract: Caffeine is a promising drug for the management of neurodegenerative diseases such as
Parkinson’s disease (PD), demonstrating neuroprotective properties that have been attributed to its
interaction with the basal ganglia adenosine A2A receptor (A2AR). However, the doses needed
to exert these neuroprotective effects may be too high. Thus, it is important to design novel
approaches that selectively deliver this natural compound to the desired target. Docosahexaenoic
acid (DHA) is the major omega-3 fatty acid in the brain and can act as a specific carrier of caffeine.
Furthermore, DHA displays properties that may lead to its use as a neuroprotective agent. In the
present study, we constructed a novel bivalent ligand covalently linking caffeine and DHA and
assessed its pharmacological activity and safety profile in a simple cellular model. Interestingly,
the new bivalent ligand presented higher potency as an A2AR inverse agonist than caffeine alone.
We also determined the range of concentrations inducing toxicity both in a heterologous system and
in primary striatal cultures. The novel strategy presented here of attaching DHA to caffeine may
enable increased effects of the drug at desired sites, which could be of interest for the treatment of PD.
Keywords: adenosine A2A receptor; caffeine; docosahexaenoic acid (DHA); inverse agonism
1. Introduction
Caffeine, the most consumed psychoactive substance worldwide, is generally used because
it enhances physical and cognitive functions, improving alertness, physical performance and
concentration, while decreasing fatigue [1,2]. Caffeine is also used as an adjuvant drug in pain
relief [3]. In addition, it has been postulated that this natural substance may have beneficial effects
in neurodegenerative diseases such as Parkinson’s disease (PD) [4]. Indeed, several epidemiological
studies have revealed an inverse relationship between caffeine consumption and the risk of developing
PD [5–7], suggesting that caffeine can act as a neuroprotective agent [8,9]. The mechanism of action of
caffeine, at non-toxic concentrations, involves interacting with and blocking adenosine receptors [10].
We recently reported that caffeine may act as an inverse agonist for adenosine A2A receptors (A2AR)
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under certain circumstances [11], suppressing constitutive A2AR activity. Interestingly, A2AR may be
over-expressed in PD, leading to increased activity within the basal ganglia [12,13], which could explain
the neuroprotective effects exerted by the inverse agonist activity of caffeine. However, the potency of
caffeine is relatively low and high doses are needed to achieve significant effects (i.e., neuroprotective
and motor effects) [14,15]. Hence, it is important to discover how to increase caffeine levels at specific
sites to promote its therapeutic effects.
One of the current approaches in drug delivery consists of using lipid carriers that help drugs
reach their target [16,17]. One of these carriers is docosahexaenoic acid (DHA), which displays
special characteristics that may potentiate its use. DHA is the major omega-3 fatty acid present in
the mammalian brain, where it is involved in a number of essential processes such as neurogenesis
and neurotransmission. Esterified DHA is found in the plasma membrane phospholipid bilayer,
where it contributes to the maintenance of its physical properties, including membrane organization,
ion permeability, elasticity and microdomain formation [18,19]. We recently showed that A2AR and
dopamine D2 receptor (D2R) expression is increased in DHA-enriched microdomains, eliciting an
increased rate of receptor oligomerization in the striatum [20]. Therefore, the rationale for attaching
caffeine to DHA (caffeine-DHA) is primarily to target the delivery of caffeine to over-expressed
striatal A2ARs. In addition to carrying caffeine to A2AR-containing membranes, DHA may also
promote its retention in the target tissue, increasing the interaction time between caffeine and A2AR.
Furthermore, DHA has been considered a neuroprotective or even a disease-modifying agent in the
treatment of PD [21]. DHA is not only considered important for optimal cognitive health and neuronal
development [22], but it has also been shown to exert neuroprotective effects in a number of studies [23].
Hence, a possible synergy between caffeine and DHA might provide additional neuroprotection, which
may lead to better management of neurodegenerative conditions.
In the present study, we aimed to design and synthesize a new bivalent ligand containing caffeine
and DHA (caffeine-DHA), and to characterize its pharmacological activity and possible toxicity in a
simple cellular model.
2. Results and Discussion
Caffeine and DHA were used to synthesize the caffeine-DHA bivalent ligand (Figure 1), using
the synthetic procedure presented in Figure 2. Briefly, reaction of the acid-functionalized caffeine
precursor (1) with tert-butyl (4,15-dioxo-8,11-dioxa-2,5,14-triazahexa-decan-16-yl)(methyl)carbamate
(2), using 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) as a coupling reagent, enabled the
introduction of the selected spacer and linker groups into the caffeine scaffold, thereby yielding the
caffeine derivative (3). Cleavage of the Boc group at (3), by treatment with TFA at 0 ◦C, and the
subsequent coupling of (4) with DHA (5) under typical coupling conditions (EDC) provided a rapid
way of generating the caffeine-DHA hybrid (6).
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Figure 2. Synthesis of the caffeine-DHA hybrid structure (6). (i) Synthesis of tert-butyl (19-(1,3-dimethyl- 
2,6-dioxo-2,3-dihydro-1H-purin-7(6H)-yl)-15-methyl-2,13,16-trioxo-6,9-dioxa-3,12,15-triazanonadecyl) 
(methyl)carbamate (3); (ii) Synthesis of 4-(1,3-dimethyl-2,6-dioxo-2,3-dihydro-1H-purin-7(6H)-yl)-N-
(4,15-dioxo-8,11-dioxa-2,5,14-triazahexadecan-16-yl)-N-methylbutanamide (4); (iii) Synthesis of (4E,7E, 
10E,13E,16E,19E)-N-(19-(1,3-dimethyl-2,6-dioxo-2,3-dihydro-1H-purin-7(6H)-yl)-15-methyl-2,13,16-
trioxo-6,9-dioxa-3,12,15-triazanonadecyl)-N-methyldo-cosa-4,7,10,13,16,19-hexaenamide (6). 
Drug development is based on characterizing two main aspects of the novel molecules, the 
pharmacological activity and the possible toxicity. Here, we performed in vitro screening to examine 
the intrinsic activity and toxicity of caffeine-DHA. First, we evaluated the effects of the novel drug 
on A2AR activity by measuring cAMP accumulation, which results from A2AR-dependent canonical 
intracellular signaling [24]. The effects of caffeine-DHA on cAMP production induced by CGS21680 
(an A2AR selective agonist) in cells expressing A2AR were evaluated. At 200 nM, CGS21680 induced an 
increase in cAMP levels of ~75% compared to the control (forskolin-induced cAMP accumulation at 
100%). Caffeine-DHA dose-dependently inhibited CGS21680-mediated cAMP accumulation (Figure 3a), 
confirming that the novel drug could bind to A2AR. In addition, the efficacy of caffeine-DHA in 
suppressing cAMP accumulation was greater than that of caffeine administered alone or with DHA at 
equimolar concentrations. The efficacy of caffeine was not significantly affected when not covalently 
bound to DHA, indicating that being covalently bound to DHA had a major effect on caffeine potency. 
To evaluate the effect of caffeine-DHA on basal cell signaling, we administered increasing concentrations 
of the drug in the absence of an A2AR-selective agonist. Caffeine-DHA increased cAMP levels (Figure 3b), 
while caffeine alone or co-administered with DHA had no effect. Of note, neither caffeine alone nor 
caffeine with DHA affected cAMP production in mock cells not expressing A2AR (data not shown).  
It should also be noted that caffeine at higher concentrations also elevated cAMP levels (data not 
shown), as previously described [11], thus indicating that both caffeine-DHA and caffeine are inverse 
agonists of A2AR, with caffeine-DHA exhibiting a higher potency than caffeine alone. 
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Figure 3. Evaluation of caffeine-DHA intrinsic activity. (a) cAMP measurements in A2AR-expressing 
cells incubated with a fixed concentration of CGS21680 (200 nM) in the absence/presence of increasing 
concentrations of caffeine (gray squares), caffeine plus DHA (black triangles) and caffeine-DHA (red 
circles). cAMP levels obtained by the CGS21680 concentration were set as 100%. Data represent the 
mean ± s.e.m. of four independent experiments. Asterisks (when comparing caffeine plus DHA and 
caffeine-DHA treatments) or hashtags (when comparing caffeine and caffeine-DHA treatments) 
indicate significant differences between drug treatments for each concentration (* p < 0.05, ** or  
## p < 0.01 and ### p < 0.001, one-way ANOVA followed by Bonferroni’s post hoc test); (b) cAMP 
measurements in A2AR-transfected cells following incubation with caffeine, caffeine plus DHA or 
caffeine-DHA. Basal cAMP levels (control) were set as 100%. Data represent the mean ± s.e.m. of four 
independent experiments. Asterisks indicate significant differences between drug treatments for each 
concentration (* p < 0.05, one-way ANOVA followed by Bonferroni’s post hoc test). 
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important in cancer therapy [25]. Here, we did not aim to develop a selective carrier for caffeine, but 
to increase the availability of caffeine in A2AR-containing sites, which would need to be properly 
assessed (i.e., by radioligand binding assays) in further studies. This strategy is not new, since a 
number of lipid-based carriers (i.e., fatty acids, glycerides and phospholipids) have been previously 
used to design lipid prodrugs (for review, see [26]). We therefore designed our drug based on the 
new concepts emerging in pharmacology, such as the residence time [27] to facilitate the drug-
receptor interaction. According to our data, caffeine-DHA exhibited a high capacity for interacting 
with A2AR, which may be due to the insertion of the DHA domain into the plasma membrane. 
Moreover, an intrinsic effect of DHA could also explain, at least in part, the results obtained, given 
that the co-administration of unmodified caffeine with DHA also produced some effects, although 
they were not significant compared to those of caffeine alone when competing with CGS21680. Recently, 
an effect of DHA on receptor complex availability in the plasma membrane was reported [20], which 
could enhance the effect of the drug being delivered. Finally, another aspect to be taken into account 
is the introduction of a spacer between the caffeine and DHA molecules. We designed this spacer to 
enable the insertion of DHA into the plasma membrane while allowing the caffeine molecule to 
interact with A2AR. However, the resulting ligand had a very high molecular weight, which could 
result in pharmacokinetic problems (i.e., distribution and the route of administration) when applied 
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lipid-based carriers (i.e., fatty acids, glycerides and phospholipids) have been previously used to
design lipid prodrugs (for review, see [26]). We therefore designed our drug based on the new concepts
emerging in pharmacology, such as the residence time [27] to facilitate the drug-receptor interaction.
According to our data, caffeine-DHA exhibited a high capacity for interacting with A2AR, which may
be due to the insertion of the DHA domain into the plasma membrane. Moreover, an intrinsic effect
of DHA could also explain, at least in part, the results obtained, given that the co-administration
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a spacer between the caffeine and DHA molecules. We designed this spacer to enable the insertion of
DHA into the plasma membrane while allowing the caffeine molecule to interact with A2AR. However,
the resulting ligand had a very high molecular weight, which could result in pharmacokinetic problems
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(i.e., distribution and the route of administration) when applied therapeutically. Thus, the length of the
spacer might need to be explored further to obtain the best compromise between pharmacodynamic
and pharmacokinetic properties.
The safety profile of the novel drug was assessed by measuring cell viability after treatment,
using the well-characterized agent propidium iodide, which is not able to insert into the DNA of intact
living cells [28]. A2AR-expressing cells incubated with caffeine-DHA at concentrations higher than
10 µM showed high mortality (Figure 4a,b). While caffeine did not induce toxicity at any concentration,
caffeine-DHA had a dramatic effect on cell viability at higher concentrations (Figure 4a,b). Interestingly,
the co-administration of caffeine and DHA also produced cell toxicity, suggesting that DHA could
be responsible for the observed cell death. A possible explanation for this toxic effect could be
that high concentrations of DHA destabilize the plasma membrane, an event that would not occur
physiologically as the tissue would buffer any lipid excess. This concentration-dependent toxicity of
caffeine-DHA was further confirmed by MTT viability assays and in neuronal cell cultures. Again, high
concentrations (100 µM) of caffeine-DHA induced cell death, as did the administration of DHA alone
or with caffeine (Figure 5a). Furthermore, primary striatal cultures were more susceptible to toxicity
than HEK293T cells, since cell survival of the primary cultures was significantly affected even at
intermediate concentrations (10 µM) (Figure 5b). Thus, caffeine-DHA exhibited adverse effects when
used at high concentrations, but was effective and safer at low concentrations. Although adverse
effects are a major issue in drug development, we showed that caffeine-DHA can be used safely,
albeit in a small range of concentrations. However, dosing in whole organisms is still a challenge and
requires a benefit/risk profile. In fact, DHA has been shown to be safe in a number of studies and is a
dietary supplement for a number of pathologies, including PD [21]. Hence, it is reasonable to continue
developing caffeine-DHA in both pre-clinical and clinical studies.
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viability levels (vehicle) were set as 100%. Asterisks indicate significant differences between drug 
treatments for each concentration (* p < 0.05 and ** p < 0.01, one-way ANOVA followed by Bonferroni’s 
post hoc test). 
3. Materials and Methods 
3.1. Drugs and Reagents 
The reagents used were forskolin from Sigma-Aldrich (St. Louis, MO, USA), and CGS21680 and 
caffeine from Tocris Bioscience (Ellisville, MO, USA). Adenosine deaminase was purchased from Roche 
Diagnostics GmbH (Mannheim, Germany) and zardaverine from Calbiochem (San Diego, CA, USA). 
Docosahexaenoic acid in the free form was a generous gift from Brudy Technology (Barcelona, Spain), 
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3.2. Synthesis of Caffeine-DHA 
3.2.1. Chemistry  
Unless otherwise indicated, all starting materials, reagents and solvents were purchased and used 
without further purification. After extraction from the aqueous phases, the organic solvents were dried 
over anhydrous Na2SO4. The reactions were monitored by thin-layer chromatography (TLC) on 2.5 mm 
Merck (Kenilworth, NJ, USA) silica gel GF 254 strips, and the purified compounds each showed a 
single spot. Unless stated otherwise, UV light and/or iodine vapor were used to detect compounds. 
Most of the preparative experiments were performed in coated vials on an organic synthesizer with 
orbital stirring. The purity and identity of all the tested compounds were established by a combination 
of HPLC, elemental analysis, mass spectrometry and NMR spectroscopy, as described below. Purification 
of isolated products was carried out by column chromatography (Kieselgel 0.040–0.063 mm, E. Merck, 
Darmstadt, Germany) or medium pressure liquid chromatography (MPLC) on a CombiFlash Companion 
(Teledyne ISCO, St, Lincoln, NE, USA) with RediSep pre-packed normal-phase silica gel columns 
(35–60 µm), followed by recrystallization. Melting points were determined on a Gallenkamp melting 
point apparatus and were uncorrected. The NMR spectra were recorded on Bruker AM300 and XM500 
spectrometers (Bruker AXS Inc., Madison, WI, USA). Chemical shifts are given as δ values against the 
internal standard tetramethylsilane and J values are given in Hz. Mass spectra were obtained on a 
Varian MAT-711 instrument (Agilent Technologies Inc., Santa Clara, CA, USA). High-resolution mass 
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containing ore tha 70 of i t t l f tt ci s ( - f tt ci c t t r ).
3.2. Synthesis of Caffeine-DHA
3.2.1. Chemistry
Unless otherwise indicated, all starting materials, reagents and solvents were purchased and used
without further purification. After extraction from the aqueous phases, the organic solvents were dried
over anhydrous Na2SO4. The reactions were monitored by thin-layer chromatography (TLC) on 2.5 mm
Merck (Kenilworth, NJ, USA) silica gel GF 254 strips, and the purified compounds each showed a single
spot. Unless stated otherwise, UV light and/or iodine vapor were used to detect compounds. Most of
the preparative experiments were performed in coated vials on an organic synthesizer with orbital
stirring. The purity and identity of all the tested compounds were established by a combination
of HPLC, elemental analysis, mass spectrometry and NMR spectroscopy, as described below.
Purification of isolated products was carried out by column chromatography (Kieselgel 0.040–0.063 mm,
E. Merck, Darmstadt, Germany) or medium pressure liquid chromatography (MPLC) on a CombiFlash
Companion (Teledyne ISCO, St, Lincoln, NE, USA) with RediSep pre-packed normal-phase silica gel
columns (35–60 µm), followed by recrystallization. Melting points were determined on a Gallenkamp
melting point apparatus and were uncorrected. The NMR spectra were recorded on Bruker AM300
and XM500 spectrometers (Bruker AXS Inc., Madison, WI, USA). Chemical shifts are given as δ
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values against the internal standard tetramethylsilane and J values are given in Hz. Mass spectra
were obtained on a Varian MAT-711 instrument (Agilent Technologies Inc., Santa Clara, CA, USA).
High-resolution mass spectra were obtained on an AutoSpec Micromass spectrometer (Micromass Inc.,
Cary, NC, USA). Analytical HPLC was performed on an Agilent 1100 system (Agilent Technologies
Inc., Santa Clara, CA, USA) using an Agilent Zorbax SB-Phenyl, 2.1 mm × 150 mm, 5 µm column with
gradient elution using the mobile phases (A) H2O containing 0.1% CF3COOH and (B) MeCN at a flow
rate of 1 mL/min. The purity of all the tested compounds was >95%.
3.2.2. Synthesis of tert-Butyl (19-(1,3-dimethyl-2,6-dioxo-2,3-dihydro-1H-purin-7(6H)-yl)-15-methyl-
2,13,16-trioxo-6,9-dioxa-3,12,15-triazanonadecyl)(methyl)carbamate (3)
To a mixture of the acid-functionalized caffeine precursor (1) (133 mg, 0.5 mmol), the N-Boc-
protected sarcosine-amide derivative (2) (292 mg, 0.75 mmol) and DMAP (67 mg, 0.55 mmol)
in DCM (15 mL) were added in N-[(dimethylamino)propyl]-N’-ethylcarbodiimide hydrochloride
(115 mg, 0.6 mmol) at room temperature. The reaction mixture was stirred overnight at room
temperature, concentrated and the residue dissolved in ethyl acetate and washed with water. The ethyl
acetate layer was dried over sodium sulfate and concentrated to give the crude product, which was
chromatographed on silica gel using DCM/MeOH to yield 229 mg (72%) of the product as a white
solid. LCMS purity was 98.7% and m.p. 195–196 ◦C. 1H-NMR (300 MHz, CDCl3) δ (ppm): 7.33
(t, J = 7.5 Hz, 1H), 7.18 (s, 1H), 6.75 (t, J = 7.4 Hz, 1H), 4.20–4.09 (m, 2H), 3.98 (s, 2H), 3.88 (s, 2H),
3.67–3.47 (m, 10H), 3.46–3.36 (m, 2H), 3.02 (s, 3H), 2.96 (s, 3H), 2.86 (s, 6H), 2.37 (t, J = 6.0 Hz, 2H),
2.09–1.93 (m, 2H), and 1.27 (s, 9H). HRMS (CI) m/z calculated for C28H47N8O9 [M + H]+ was 639.3463
and found to be 639.3468.
3.2.3. Synthesis of 4-(1,3-Dimethyl-2,6-dioxo-2,3-dihydro-1H-purin-7(6H)-yl)-N-(4,15-dioxo-8,11-dioxa-
2,5,14-triazahexadecan-16-yl)-N-methylbutanamide (4)
TFA (0.25 mL, 3.3 mmol) was added to a solution of the caffeine derivative (3) (200 mg, 0.3 mmol)
in dichloromethane (15 mL) at 0 ◦C. The reaction mixture was removed from the ice bath and
stirred at room temperature for 3 h. The solvents were removed in vacuo and the residue diluted
with dichloromethane. The mixture was neutralized with saturated aqueous sodium bicarbonate.
The organic layer was separated, dried (sodium sulfate) and concentrated in vacuo to provide the
crude product, which was chromatographed on silica gel using DCM/MeOH to yield 136 mg (81%)
of the product as a white solid. LCMS purity was 98.4% and m.p. 214–215 ◦C. 1H-NMR (300 MHz,
CDCl3) δ (ppm): 7.38 (t, J = 7.6 Hz, 1H), 7.21 (s, 1H), 6.70 (t, J = 7.6 Hz, 1H), 4.15–4.04 (m, 2H), 3.95
(s, 2H), 3.81–3.72 (m, 2H), 3.61–3.42 (m, 10H), 3.39–3.19 (m, 3H), 3.04 (s, 3H), 2.87 (s, 6H), 2.67 (s, 3H),
2.41 (t, J = 6.2 Hz, 2H), and 2.10–1.94 (m, 2H). HRMS (CI) m/z calculated for C23H39N8O7 [M + H]+
was 539.2938 and found to be 539.2942.
3.2.4. Synthesis of (4E,7E,10E,13E,16E,19E)-N-(19-(1,3-Dimethyl-2,6-dioxo-2,3-dihydro-1H-purin-7(6H)-
yl)-15-methyl-2,13,16-trioxo-6,9-dioxa-3,12,15-triazanonadecyl)-N-methyldo-cosa-4,7,10,13,16,19-
hexaenamide (6)
To a mixture of DHA (5) (50 mg, 0.15 mmol), the sarcosinamide-functionalized caffeine
precursor (4) (100 mg, 0.187 mmol) and DMAP (20 mg, 0.165 mmol) in DCM (20 mL) were added
in N-[(dimethylamino)propyl]-N’-ethylcarbodiimide hydrochloride (35 mg, 0.18 mmol) at room
temperature. The reaction mixture was stirred overnight at room temperature, concentrated and
the residue dissolved in ethyl acetate and washed with water. The ethyl acetate layer was dried over
sodium sulfate and concentrated to give the crude product, which was chromatographed on silica gel
using EtOAc/MeOH to give 57 mg (45%) of the product as a pale yellow oil. LCMS purity was 97.2%.
1H-NMR (300 MHz, CDCl3) δ (ppm): 7.21 (s, 1H), 7.00 (brs, 1H), 6.82 (brs, 1H), 5.47–5.22 (m, 12H),
4.27–4.15 (m, 2H), 4.02 (s, 2H), 3.99 (s, 2H), 3.61–3.36 (m, 12H), 3.09 (s, 3H), 3.05 (s, 3H), 2.91 (s, 3H), 2.85
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(s, 3H), 2.48–2.26 (m, 10H), 2.19–1.92 (m, 10H), and 0.96 (t, J = 7.5 Hz, 3H). HRMS (ESI) m/z calculated
for C45H69N8O8 [M + H]+ was 849.5236 and found to be 849.5244.
3.3. Plasmids and Transfection
The cDNA encoding the A2ARSNAP [29] was used. Human embryonic kidney (HEK)293T cells
were grown at 37 ◦C, 5% CO2, in Dulbecco’s modified Eagle’s medium (DMEM) (Sigma-Aldrich,
Saint Louis, MO, USA) supplemented with 1 mM sodium pyruvate, 2 mM L-glutamine, 100 U/mL
streptomycin, 100 mg/mL penicillin and 5% (v/v) fetal bovine serum. Cells were seeded on to
six-well plates at 300,000 cells/well and transiently transfected using Transfectin (Bio-Rad Laboratories,
Hercules, CA, USA), following the manufacturer’s instructions.
3.4. Animals and Neuronal Cultures
CD-1 mice (from the animal facility of the University of Barcelona) weighing 20–25 g were used.
The University of Barcelona’s Committee on Animal Use and Care approved the protocol. Animals
were housed and tested in compliance with the guidelines described in the Guide for the Care and
Use of Laboratory Animals [30] and followed European Union directives (2010/63/EU). All efforts
were made to minimize animal suffering and the number of animals used. All animals were housed in
groups of five in standard cages with ad libitum access to food and water, and maintained under a
12 h dark/light cycle (starting at 7:30 a.m.) and at 22 ◦C and 66% humidity (standard conditions).
Primary striatal neurons were cultured from E18 CD-1 mouse embryos. Briefly, after dissection,
the striatum was treated with 1.25% trypsin (Sigma-Aldrich, St. Louis, MO, USA) for 10 min and
mechanically dissociated with a flame-polished Pasteur pipette. Neurons were plated onto poly-D-
lysine–coated (0.1 mg/mL) and laminin-coated (0.01 mg/mL) wells at a density of 80,000 cells/cm2 on a
six-well plate for cAMP accumulation assays in minimum essential medium (Invitrogen, Carlsbad, CA,
USA) supplemented with 10% horse serum, 10% bovine serum, 1 mM pyruvic acid and 0.59% glucose.
After 4–14 h, the medium was substituted with Neurobasal medium supplemented with penicillin
(100 U/mL), streptomycin (100 µg/mL), 0.59% glucose and B27 supplement (Invitrogen Carlsbad, CA,
USA). Neurons were kept at 5% CO2, 37 ◦C and 95% humidity for 21 days before the experiments.
3.5. cAMP Accumulation Assay
cAMP accumulation was measured using the LANCE® Ultra cAMP kit (PerkinElmer, Waltham,
MA, USA), as previously described [31]. Briefly, cells were incubated for 1 h at 37 ◦C with stimulation
buffer (0.1% bovine serum albumin (BSA), 0.5 units/mL of adenosine deaminase and 2 µM zardaverine
in serum-free DMEM) and later with the different drugs for 30 min at 37 ◦C. Thereafter, cells were
transferred to a 384-well plate in which reagents were added following the manufacturer’s instructions.
After 1 h at room temperature, TR-FRET was determined by measuring light emission at 620 nm and
665 nm using a POLARstar plate reader (BMG Labtech, Durham, NC, USA).
3.6. Propidium Iodide Assay
Cell viability was evaluated by assessing the amount of propidium iodide penetrating living cells,
as previously described [32]. Briefly, A2AR-expressing cells treated with the drug for 3 h were incubated
with propidium iodide (Sigma-Aldrich; 10 µM) for 30 min at 37 ◦C. After two wash steps with Hank’s
Balanced Salt Solution (HBSS; containing, in mM, 137 NaCl, 0.34 Na2HPO4, 5 KCl, 0.44 KH2PO4,
0.5 MgCl2, 0.4 Mg2SO4, 1.26 CaCl2, 10 HEPES, 2 D-glucose and 1 ascorbic acid; adjusted to pH 7.4 with
NaOH), light emission at 630 nm was measured after excitation at 495 nm in a POLARstar plate reader
or the cells were visualized in a FLoid Cell Imaging Station (Life Technologies, Carlsbad, CA, USA).
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3.7. MTT Assay
Drug toxicity was evaluated by measuring the cellular uptake of 3-(4,5-dumethylthiazol-2-
yl)-2,5-iphenyltetrazolium bromide (MTT), as previously described [33]. Briefly, A2AR-expressing cells
treated with the drug for 3 h were incubated with a solution of MTT (Sigma-Aldrich; 0.5 mg/mL) in
HBSS for 30 min at 37 ◦C. The tetrazolium ring of MTT is cleaved by active dehydrogenases in living
cells to produce a precipitated formazan salt that is solubilized by DMSO to give a colored compound.
After stirring the mixture for 5 min, optical density was measured at 540 nm in the POLARstar plate
reader to determine the rates of cell death.
3.8. Statistical Analysis
The number of samples (n) in each experimental condition is indicated in the figure legends.
Statistical analysis was performed by one-way ANOVA followed by Bonferroni’s multiple comparison
post hoc test. Statistical significance is indicated for each experiment.
4. Conclusions
We have synthesized a novel drug by combining caffeine and DHA using a simple and efficient
synthetic procedure. This ligand, caffeine-DHA, is a more potent A2AR inverse agonist than caffeine
alone. Our cell viability experiments showed that high concentrations of caffeine-DHA produced
cell toxicity. Nevertheless, taking into consideration its pharmacological activity, caffeine-DHA is a
promising drug for targeting A2AR in pathologies in which its constitutive activity is altered (i.e., PD).
Finally, our approach of attaching DHA to a small drug may be a good model for future drug
discovery studies.
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